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Periosteum is vital for fracture healing, as a highly vascular and multipotential stromal cell- (MSC-) rich tissue. During surgical
bone reconstruction, small fragments of periosteum can be “clinically accessible,” yet periosteum is currently not ultilised, unlike
autologous bone marrow (BM) aspirate. This study is aimed at comparing human periosteum and donor-matched iliac crest
BM MSC content and characterising MSCs in terms of colony formation, growth kinetics, phenotype, cell migration patterns,
and trilineage diﬀerentiation capacity. “Clinically accessible” periosteum had an intact outer ﬁbrous layer, containing CD271+
candidate MSCs located perivasculary; the inner cambium was rarely present. Following enzymatic release of cells, periosteum
formed signiﬁcantly smaller ﬁbroblastic colonies compared to BM (6.1mm2 vs. 15.5mm2, n = 4, P = 0:0006). Periosteal colonies
were more homogenous in size (range 2-30mm2 vs. 2-54mm2) and on average 2500-fold more frequent (2.0% vs. 0.0008%,
n = 10, P = 0:004) relative to total viable cells. When expanded in vitro, similar growth rates up to passage 0 (P0) were seen
(1.8 population doublings (PDs) per day (periosteum), 1.6 PDs per day (BM)); however, subsequently BM MSCs proliferated
signiﬁcantly slower by P4 (4.3 PDs per day (periosteum) vs. 9.3 PDs per day (BM), n = 9, P = 0:02). In early culture, periosteum
cells were less migratory at slower speeds than BM cells. Both MSC types exhibited MSC phenotype and trilineage diﬀerentiation
capacity; however, periosteum MSCs showed signiﬁcantly lower (2.7-fold) adipogenic potential based on Nile red : DAPI ratios
with reduced expression of adipogenesis-related transcripts PPAR-γ. Altogether, these data revealed that “clinically accessible”
periosteal samples represent a consistently rich source of highly proliferative MSCs compared to donor-matched BM, which
importantly show similar osteochondral capacity and lower adipogenic potential. Live cell tracking allowed determination of
unique morphological and migration characteristics of periosteal MSCs that can be used for the development of novel bone graft
substitutes to be preferentially repopulated by these cells.
1. Introduction
Fracture nonunion represents a signiﬁcant clinical challenge.
The rate of fracture nonunion is reported to be between 2 and
10% of all fractures, dependent on fracture type, location, and
patient demographics [1, 2]. Its treatment is not only costly to
healthcare providers [3], but importantly to the patients
through loss of earnings and high rates of depression, all of
which will have a detrimental eﬀect on quality of life [4].
Therefore, improvements to standard-of-care treatments of
bone fracture are needed and have been recently developed
based on the diamond concept framework [5], which draws
attention to the importance of ensuring the presence of all:
osteogenic cells, osteoconductive scaﬀolds, osteoinductive
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growth factors and a stable mechanical environment at the
site of healing [5]. Most commonly, osteogenic cells are deliv-
ered to the fracture site in the form of bone marrow aspirate
(BMA), BMA concentrate (BMAC), or combining BMAC
with grafting material to ﬁll larger defects to aid with fracture
repair [6–10].
The critically important role of periosteum during bone
fracture healing is well established. Following fracture perios-
teum reacts by thickening and entering into a proliferative
state [11–13]. Periosteal-derived progenitor cells migrate into
the fracture haematoma early on, where they diﬀerentiate
into osteoblasts or chondrocytes, directly contributing to
bone regeneration [12]. Periosteal stripping or damage dur-
ing fracture results in decreased callus formation or delayed
union [13–16]. However, despite the known critical impact
of periosteum during fracture repair, the use of periosteal-
derived cells for surgical repair of fractures, nonunions, or
critical size bone defects remains unexploited.
Periosteum lines the outer aspect of most bones, contrib-
uting to appositional growth during childhood and adoles-
cence as well as providing the vascular supply to bone [14].
This tissue, although thin, forms two distinct layers, the bone
lining inner cambium layer being highly cellular and contain-
ing osteogenic progenitors, while the outer ﬁbrous layer, pre-
dominantly consisting of collagen, is highly vascular but not
particularly cellular in comparison [12, 17]. The cambium
layer is tightly attached to the underlying bone by Sharpey’s
Fibres; thus, removal of periosteum with the cambium layer
attached is diﬃcult [18] and is furthermore considered inap-
propriate by the surgeons as potentially compromising the
repair process. However, “clinically accessible” samples of
periosteum, likely to be ﬁbrous in nature, can be obtained
as by-products of surgical debridement of the fracture site,
but their osteogenic progenitor cell content has not yet been
explored before.
The purpose of this study was to investigate “clinically
accessible” samples of human periosteum for the presence
of osteogenic progenitor multipotential stromal cells (MSCs)
and to compare their functional capacities with iliac crest
BMA samples from the same donors.
2. Materials and Methods
2.1. Tissue Collection and Processing. Donor-matched sam-
ples of periosteum and BMA were obtained from 12 patients
treated for fracture nonunion (median age 49 years, range
17-80) at the Trauma Orthopaedic Unit at Leeds General
Inﬁrmary, Leeds, UK. Periosteum (approximately 50mm2,
0.3 g) was harvested from near to the site of fracture using a
scalpel, and BMA (volume range 16-60mL) was aspirated
from the anterior iliac crest. Iliac crest trabecular bone
(approximately 1 cm3) was collected from three patients,
undergoing autograft procurement. Ethical approval was
granted by the National Research Ethics Committee–Leeds
East, with ethical approval number 06/Q1206/127 and
informed written consent given by all patients.
For extraction of periosteum- and BMA-resident nucle-
ated cells, BMA underwent processing with ammonium
chloride (Stem Cell Technologies) to lyse red blood cells.
Brieﬂy, 4mL of ammonium chloride solution was added
per 1mL of BMA and incubated for 10mins on ice. Cells
were concentrated via centrifugation (650 g, 5mins). Perios-
teum samples were digested in collagenase (600U/mL, Stem
Cell Technologies) at a ratio of 0.1 g of tissue to 0.5mL of col-
lagenase, for 4 h, incubated at 37°C, 5% CO2. After digestion,
the cell suspension was passed through a 70μm cell strainer
to remove large debris; the cell suspension was concentrated
via centrifugation (650 g, 5mins). Cells were used directly for
in vitro assays, as described in the subsequent sections.
2.2. Histology of Periosteum. Human periosteum and iliac
crest bone samples were ﬁxed in 3.75% formaldehyde for a
week, and iliac crest bone was next decalciﬁed using 0.1M
EDTA. Subsequently, samples were embedded in paraﬃn
wax, and 5μm thick slides were produced (SuperFrost Plus
slides). Slides were dewaxed and hydrated using standard
methods, followed by staining for haematoxylin and eosin
and picro sirius red. Samples were also stained for CD271
(1 : 20, NGFRS, Abcam), the well-recognised marker of
bone-resident MSCs [19]. Antigen retrieval was carried out
using 10mM/L citrate buﬀer, and immunohistochemistry
was carried out using the Dako EnVision kit (Dako), as per
themanufacturer’s guidelines. Post staining, slides were dehy-
drated and cleared with xylene and covered with a coverslip,
using DPX (Sigma). Slides were imaged using light micros-
copy (AxioCam MRc5, Zeiss) and under a polarised light.
2.3. Colony-Forming Fibroblast (CFU-F) Assay. CFU-F assays
were used to quantify colony-forming cells in BMA and
periosteum digest samples and performed as previously
described [20, 21]. After 14 days of culture in StemMACS
MSC expansion media (Miltenyi Biotec, supplemented with
1% penicillin streptomycin), duplicate dishes were ﬁxed,
stained [20], and scanned. Colonies were counted and colony
surface area was quantiﬁed using ImageJ [22]. The frequency
distribution of colony surface area was plotted using
Prism. The spread of colony surface area distribution data
was quantiﬁed using “full width at half maximum” (FWHM)
values [23].
2.4. MSC Expansion and Surface Marker Characterisation.
Following initial processing, nucleated cells from BMA and
periosteum were plated at a density of 4 × 105 per cm2 and
1 × 104 per cm2, respectively, and incubated at 37°C, 5%
CO2 in StemMACS media. After 48 hours, media were
replaced and cells were cultured until 60-80% conﬂuence
with biweekly half medium changes; ﬂasks were trypsinised
and reseeded at cell densities of 1:25 × 105 for periosteum
[24] and 2:5 × 105 for BM [25], this was repeated until pas-
sage 6. Population doubling (PD) up to passage 0 (<P0)
and after passage 0 (>P0) was calculated as follows: PD
ð<P0Þ = log2 ðcell count at passage 0/seeded number of CFU
− FÞ and PD ð>P0Þ = log2ðcell count at passage/seeded cell
countÞ as per Churchman et al. [26].
To conﬁrm the MSC nature of expanded cells, ﬂow
cytometry of donor-matched BM and periosteum cultures
was carried out using antibodies chosen in line with the
International Society for Cellular Therapies (ISCT) approved
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panel (Supplementary Table 1) [27], as previously described
by [28]. In brief, trypsinised cells were resuspended in
blocking buﬀer (10% mouse serum, 1% human IgG in FACS
buﬀer (0.1% BSA, 0.01% sodium azide, 0.5M EDTA in
PBS)) for 15mins at RT and stained with antibodies
(Supplementary Table 1) for 30mins on ice. Following one
wash in FACS buﬀer, cells were resuspended in 500μL
4′,6-diamidino-2-phenylindole (DAPI) buﬀer ready to be
analysed by an LSRII ﬂow cytometer (BD Pharmingen).
Data was analysed using FACS DIVA software.
2.5. In Vitro Trilineage Diﬀerentiation Assays. Cultured cells
(passage 1-3) from donor-matched periosteum and BM
underwent trilineage diﬀerentiation assessment; OsteoDIFF,
AdipoDIFF, and ChondroDIFFmedia (Miltenyi Biotec) were
used to induce diﬀerentiation. For osteogenesis (n = 7
donors), 2600 cells/cm2 were plated onto 7 replicate ﬂat
bottom wells and incubated at 37°C, 5% CO2 in OsteoDIFF
for 2 or 3 weeks, with biweekly, half medium changes. At
two weeks, alkaline phosphatase (ALP) activity was detected
using fast blue. At three weeks, calcium deposition was
stained with alizarin red [29] and calcium content was mea-
sured, as previously described [28]. For three donors, an extra
well was set up to measure DNA content, cells were lysed in
200μL of 0.1% Triton-X 100, and DNA content was quanti-
ﬁed using a PicoGreen Assay (Thermo Scientiﬁc) [30].
Adipogenesis assays were seeded at 4200 cells/cm2 into 5
replicate ﬂat bottomed well plates, incubated at 37°C, 5%
CO2, and half medium (AdipoDIFF) changes were carried
out biweekly for 3 weeks. After 3 weeks, plates were ﬁxed
with 3.75% formaldehyde and stained with either oil red
(n = 6 donors) or Nile red and DAPI (n = 3 donors) [31],
the latter of which was quantiﬁed using a ﬂuorescent plate
reader (Berthold) and Nile red absorbance levels were
normalised to DAPI absorbance levels to establish Nile
red/DAPI ratios [31].
Chondrogenic assays (n = 5 donors) were carried out in 5
replicate 1.5mL screw cap Eppendorf tubes; 2:5 × 105 cells
were added to each tube and centrifuged (800 g, 5mins) to
create a pellet culture and was resuspended in ChondroDIFF
media. Tubes were placed in an incubator at 37°C, 5% CO2
for 3 weeks, where half medium changes were made three
times a week. After 3 weeks, 2 pellets were snap frozen in
OCT, cut using a cryostat (Leica Biosystems), and dried onto
histology slides where toluidine blue was used to stain GAGs.
The remaining three pellets were digested in papain digest
buﬀer at 65°C overnight, and the GAG content was quanti-
ﬁed using a sulphated GAG assay kit (Blyscan), as previously
described [28].
Extra wells or pellets were set up for each trilineage diﬀer-
entiation assay for 3 donors to allow quantiﬁcation of change
expression of key lineage markers following diﬀerentiation
induction. Cells were lysed and RNA isolated using a Single
Cell RNA Puriﬁcation Kit (Norgen) and on-column DNase
(Applied Biosystems) treatment. cDNA was produced using
a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems) for use with TaqMan assays: osteogenesis
markers—runt-related transcription factor 2 (RUNX2)
and bone gamma-carboxyglutamate (gla) protein (BGLAP);
chondrogenesis markers—collagen, type 2, alpha 1 (COL2A1)
and SRY- (sex-determining region Y-) box 9 (Sox9); and
adipogenesis markers—fatty acid-binding protein 4 (FABP4)
and peroxisome proliferator-activated receptor-gamma
(PPAR-γ). The real time-PCR (RT-PCR) reaction was run
using a QuantStudio™ 7 Flex Real-Time PCR System and
SDS software, recording the ﬂuorescence in real time.
Analysis was carried out using the 2-Δ(Ct) method, to calculate
normalised gene expression (normalised to hypoxanthine
phosphoribosyltransferase 1 (HPRT1) expression) [32].
2.6. Live Holographic Imaging. P0 vials of donor-matched
(male, 17) BM and periosteum MSCs were seeded in dupli-
cate (250 cells per well) onto a Lumox® multiwell 24-well cell
culture plate (Sarstedt). The cultures were grown for 3 days at
37°C, 5% CO2 in StemMACS media. On day 3, following a
half medium change, the plate lid was replaced with PHI
HoloLids™ imaging covers (PHI, phase holographic imag-
ing) (sterilised in 70% EtOH, 10mins). The plate was placed
onto the xy motorised stage of a HoloMonitor M4 Micro-
scope, set up inside an incubator. Using the Hstudio soft-
ware, three coordinates in each well were manually focused
and set to automatically image every hour for 2 days.
Post acquisition, the Hstudio software applied a “mask”
to the images, where a threshold was set to distinguish cells
from the bottom of the well, allowing for automatic cell iden-
tiﬁcation. Automatic cell number assignment allowed for
individual cell tracking over time, which was checked manu-
ally. All outputs were exported into Excel ﬁles and plotted
using Prism.
2.7. Statistical Analysis. To compare donor-matched perios-
teum and BM samples, statistical analysis was carried out
using appropriate paired tests (Wilcoxon signed-rank test
or paired t test depending on data distributions), where
P < 0:05 was considered signiﬁcant. Phase holographic
imaging data sets were compared using an unpaired Student’s
t-test. The exact tests are speciﬁed in the ﬁgure legends, and
the data is presentedmean ± standard deviation.
3. Results
3.1. Location of CD271+ Candidate MSCs in Human
Periosteum and Iliac Crest Bone. The architecture of human
samples of periosteum (n = 5), taken from the femur and
humerus (n = 1), approximately 5 cm from a nonunion frac-
ture site (within the surgical opening) was assessed. The
mean donor age was 51:8 ± 24:6 years (range, 23-80 years),
and periosteum samples were harvested 50 ± 37 weeks
following initial injury, with each patient having undergone
0-2 previous orthopaedic surgeries (Table 1). In all the
samples, apart from one (male, 47) (Figures 1(a)–1(c)), no
cambium layer could be seen, reﬂecting the preferential
harvesting of periosteum ﬁbrous layer, as expected. When
an intact cambium layer was seen (Figures 1(a) and 1(b)), it
was shown to be attached to the underlying bone. Here, the
periosteum could be clearly split into the bone lining
cambium layer and the muscle facing ﬁbrous layer.
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Table 1: Breakdown of patient demographics, with respect to location of periosteum retrieval and time since initial injury for histological
analysis and cellular work.
Sex & age (years) Harvested from Time since injury (weeks) Previous surgeries Surgery carried out
Histology
M, 23∗ Femur 57 2 IMN
M, 35∗ Humerus 108 None Bone graft with BMAC
M, 47 Femur 19 None RIA graft
F, 74∗ Femur 49 2 IMN, bone graft
F, 80 Femur 17 2 2nd stage Masquelet
Cellular work
M, 17 Femur 65 2 IMN
M, 44 Tibia 11 1 IMN
F, 49 Femur 155 1 IMN
M, 49 Femur 12 1 Plate ﬁxation
M, 55 Femur 41 1 2nd stage Masquelet
M, 58 Tibia 71 1 Bone graft
M, 59 Femur 127 2 Locking plate
M: male, F: female, none: sample harvested during ﬁrst orthopaedic surgery, IMN: intramedullary nailing, BMAC: bone marrow aspirate concentrate, RIA:
reamer irrigator aspirator, ∗sample also used for cellular work.
C CBF
(a)
C
CB
F
(b)
CF
(c) (d)
Figure 1: Histological staining of human periosteum samples, harvested close to a fracture site. (a) H&E staining of periosteum sample
showing the cellular inner cambium layer (C), the lining cortical bone (CB), and the outer ﬁbrous layer (F). (b) Picro sirius red, imaged
using polarised light, showed collagen as the dominant feature of periosteum. CD271 candidate MSC marker immunohistochemistry
staining was carried out on (c) periosteum, where staining was shown in the cambium layer and surrounding blood vessels throughout the
ﬁbrous layer and (d) iliac crest bone samples, where staining was within the bone marrow and lining the bone.
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To investigate the location of candidateMSCs throughout
the periosteum, CD271 staining was carried out. CD271 pos-
itivity was found throughout both layers of the periosteum,
localised to the outer edge of blood vessels (Figure 1(c)).
CD271 positivity was also seen in the BM cavities of the
control iliac crest bone as expected (Figure 1(d)) [33].
3.2. Colony Formation and Growth Kinetics of Periosteum-
Derived Cultures. CFU-F assays were carried out to quantify
colony formation as a measure of MSC frequency in donor-
matched iliac crest BM and periosteum samples (n = 10)
(Figures 2(a) and 2(b)). The mean donor age was 46:3 ±
17:3 years (range, 17-74 years), periosteum was harvested
mainly from the femur (n = 7), but also the tibia (n = 2) and
humerus (n = 1), all from nonunion cases, 70 ± 47 weeks
following initial injury, and patients had undergone 0-2
previous orthopaedic surgeries.
In the BM, CFU-F frequency in relation to total nucleated
cells was on average 0:0008 ± 0:0002% consistent with
previous studies [21, 34]. In donor-matched periosteum
digests, CFU-F frequency was signiﬁcantly (P = 0:004,
Wilcoxon signed-rank test) higher (2500-fold) (2:0 ± 0:6%)
(Figure 2(b)).
In order to assess the visual diﬀerences in colony forma-
tion (Figure 2(a)), colony surface area was quantiﬁed, from
donor-matched dishes containing more than 20 colonies
(n = 4). Periosteum colonies were more homogenous, with
a smaller size distribution compared to BM colonies
(Figure 2(c)), which were more heterogeneous and larger. Peri-
osteum colonies were signiﬁcantly smaller at 6:1 ± 0:6mm2
(range, 2.0-29.6mm2) compared to BM colonies at 15:5 ±
0:8mm2 (range, 2.1-54.3mm2) (paired Student’s t-test,
P = 0:0006) (Figure 2(d)). Of particular interest was that
BM had a subset of larger colonies > 30mm2, accounting
for 6:4 ± 2:2% of all BM colonies, which were not seen in
periosteum samples.
Growth kinetics of donor-matched BM and periosteum
cultures was next investigated, and two clear growth patterns
were noticeable (Figures 2(e) and 2(f)) and thus split before
P0 (<P0) and after P0 (>P0) for the analysis. Growth rates
measured as PDs per day for <P0 cultures were similar
between BM (1:6 ± 0:1 days per PD) and periosteum
(1:8 ± 0:2 days per PD), also shown through similar slope
gradient (0.50 (BM) and 0.52 (P)) following linear regression
analysis (r2 values, 0.87 (BM) and 0.91 (periosteum))
(Figure 2(e)). However, diﬀerences could be seen following
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Figure 2: Quantiﬁcation of MSC content, colony formation, and in vitro proliferation of periosteum and bone marrow-derived MSCs.
(a) Colonies formed by MSCs during CFU-F assays. (b) Percentage MSCs in nucleated cell count. (c) Quantiﬁcation of colony surface area
(n = 4) distribution (Gaussian distribution). (d) Mean colony size (n = 4). (e) In vitro proliferation of MSCs, calculated by cumulative
population doublings, showing two distinct growth curves prior to passage (<P0) and post passage (>P0). (f) Days per population
doubling compared from P0 to P4. (g) Flow cytometry histograms for positive and negative MSC markers. Statistical analysis was carried
out, Wilcoxon signed-rank test ∗∗P = 0:004 (a), paired Student’s t-test ∗∗∗P = 0:0006 (d), Kruskal-Wallis test (comparison of P0 to P1-P4)
∗P < 0:02, ∗∗P < 0:001 (f), and Wilcoxon signed-rank test (comparison of bone marrow to periosteum) ∗P < 0:05 (f). BM: bone marrow
(black), P: periosteum (grey), NCC: nucleated cell, PD: population doubling.
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quantiﬁcation of number of PDs at P0; BM cultures were
started with a lower number of MSCs compared to perios-
teum (Figure 2(b)) and therefore went through signiﬁcantly
higher number of PDs (BM: 13:3 ± 0:5 PDs at P0, peri-
osteum: 8:5 ± 1:1 PDs at P0, Wilcoxon signed-rank test,
P = 0:02).
Following the ﬁrst passage, the PD rate signiﬁcantly slo-
wed (P1-P4) for both culture types (Figures 2(e) and 2(f)),
by P4 proliferation rates were reduced to 9:3 ± 3:2 days
per PD (BM) and 4:3 ± 0:5 days per PD (periosteum)
(Figure 2(f)). The ISCT MSC phenotype was tested on
donor-matched cultures [27] at passage 4, and both cul-
ture types were >91% positive for MSC markers CD73
(ecto-5′-NT), CD90 (Thy1), and CD105 (Endoglin) and
<3% positive for hematopoietic lineage markers: CD14
(monocyte diﬀerentiation antigen), CD19 (B-lymphocyte
antigen), CD34 (haematopoietic progenitor cell antigen),
CD45 (haematopoietic cell marker), and HLA-DR (MHC
class II cell surface receptor) (Figure 2(g)).
Overall, these data revealed high CFU-F content and
a more homogenous nature of colony-forming cells in
“clinically accessible” periosteal samples, compared to
donor-matched BM samples. Additionally, in our chosen
experimental conditions, periosteum MSC cultures had
achieved lower cumulative PDs than their BM counterparts
at the same passage.
3.3. Live Cell Tracking of Periosteum and Bone Marrow MSC
Cultures. To explore if the observed diﬀerences seen in col-
ony size between periosteum and BM MSCs could be due
to diﬀerent cell migration patterns, live cell imaging and
tracking of cell movement over time was carried out using
holographic imaging. Thawed P0 cell cultures (previously
grown in culture for 13 days, 6.6 PD (periosteum) and 13
PD (BM)) were tracked from one donor (male, 17). Thawed
freshly digested periosteum cultures were grown and shown
to be not signiﬁcant to their P0 counterparts (data not
shown); therefore, P0 cultures were taken as surrogate to
represent MSC migration for up to 2 weeks in culture
(the end time point of a CFU-F assay).
Following thresholding of individual images and identiﬁ-
cation of cells, the morphology of the cells within each cul-
ture could be quantiﬁed and compared. There were two
diﬀering cell morphologies within both MSC populations.
The ﬁrst of which was “dividing” cells (Figure 3(a)), with
high average cell thickness (>2.5μm) but a small cell surface
area (<1100μm2), reﬂecting a spherical shape just prior to
cell division, which made up 2.05% (periosteum) and 2.12%
(BM) of all cells (Figures 3(b) and 3(c)). The second, which
formed the majority (97.95%: periosteum, 97.88%: BM),
was “spindle-” shaped cells (Figure 3(a)), representing the
classical MSC morphology, with an average cell thickness of
0.6-2.5μm and cell surface area ranging from 79 to
2965μm2 (Table 2).
With respect to the “dividing” cells, the average thickness
of periosteum cells (6:1 ± 2:5 μm) was signiﬁcantly higher
(unpaired Student’s t-test, P < 0:0001) than BM cells
(3:4 ± 0:6 μm); however, cell surface area was similar
(Table 2). In addition, the periosteum “spindle-” shaped cells
had signiﬁcantly higher cell surface area and cell thickness
(unpaired Student’s t-test, P < 0:0001) compared to BM cells.
Overall, these data indicated that periosteal cellsMSCs appear
to have a larger cell volume than their BM counterparts.
The cell migration and movement patterns of periosteal
and BM MSCs were assessed by live tracking of individual
cells. Maps of cell movement (Figure 4(a)) revealed visual dif-
ferences in MSC migration patterns of individual cells,
whereby some cells were relatively nonmigratory, remaining
in the same area, and other cells were seen to migrate across
the ﬁeld of view. “Cell migration” refers to the displacement
of a tracked cell from the ﬁrst measured coordinates, in
comparison to “cell motility” which refers to the cumulative
distance travelled at each time point. From three ﬁelds of
view per culture, the whole cell population was quantiﬁed
over 25 hours and mean cell migration was calculated as well
as split into the migratory (>100μm cell migration) or the
nonmigratory (<100μm cell migration) cells (Figure 4(a)).
To track changes in migration patterns over time, mean
cell migration after 5 and 20 hours of cell tracking was com-
pared. BMMSCs showed signiﬁcantly highermean cell migra-
tion (unpaired Student’s t-test, P < 0:0001 (5 hours), P = 0:001
(20 hours)) at 5 hours (102:6 ± 54:6 μm (BM), 53:5 ± 32:6 μm
(periosteum)) and 20 hours (209:1 ± 129:2 μm (BM) and
123:6 ± 67:6 μm (periosteum)) (Figure 4(b)). A similar trend
was seen with cell motility, where BM MSCs were signiﬁ-
cantly more motile over time (unpaired Student’s t-test,
P < 0:05). At 5 hours, total cell motility (distance travelled)
was 151:4 ± 53:6 μm (BM) compared to 95:6 ± 35:0 μm
(periosteum), and by 20 hours, this diﬀerence had increased
to 594 ± 136:0 μm (BM) and 384:2 ± 81:5 μm (periosteum)
(Figure 4(c)).
The proportion of nonmigratory to migratory MSCs
within the periosteum and BM cultures was 42% (n = 45)
and 63% (n = 94), respectively, suggestive that there is a
slightly lower proportion of cells classiﬁed as nonmigratory
within periosteum cultures (Table 3). When comparing non-
migratory to migratory MSCs over time, signiﬁcant increases
in cell migration or displacement away from the initial
tracked point were seen from 5 hours onwards between the
migratory and nonmigratory cells for both culture types
(unpaired Student’s t-test, P < 0:05) (Figure 4(b)). Similar
trends were seen, where cell migration steadily increased in
a linear fashion and then started to plateau; however, while
the plateau was seen at approximately 8 hours (>100μm)
and 5 hours (<100μm) for BM cultures, this was
extended to about 15 hours (<100μm) or not well deﬁned
for >100μm within periosteum cultures (Figure 4(b)).
Based on this data, it could be concluded that cell migra-
tion was not only “faster” in BM MSCs compared to their
periosteum counterparts but also “further away” from the
tracked start point (approximately 190μm (BM) vs. 150μm
(periosteum)) (Figure 4(b)), indicating that the speed of cell
movement was greater in BM cultures.
Signiﬁcant increases in cell motility or distance (rather
than displacement) migrated over time were seen with the
migratory cells (>100μm), compared to the nonmigratory
cells (<100μm) from 5 hours onwards (unpaired Student’s
t-test, P < 0:005), irrespective of culture type (Figure 4(c)).
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Cell motility was linear, irrespective of either class of migra-
tion, with r2 values of >0.994 for both culture types. There-
fore, cell speed (μm/h) was calculated from the gradient of
the cell motility graphs (Figure 4(c)); as expected, the speed
of the migratory cells was higher than the nonmigratory cells
(Table 3). Furthermore, BM MSCs were shown to migrate at
either 22.3μm/h (<100μm) or 32.0μm/h (>100μm), con-
ﬁrming that BM MSCs move with greater speed than perios-
teum MSCs (17.5μm/h (<100μm), 20.4μm/h (>100μm))
(Table 3).
Migration directness is a ratio of migration (displace-
ment) to motility (distance), where 1 refers to movement in
a straight line and 0 to a cell moving completely randomly.
This parameter can be used to calculate whether cells migrate
randomly or with apparent “purpose.” In contrast to the pre-
vious parameters, no signiﬁcant diﬀerences were seen
between the MSC culture types over time (Figure 4(d)). Cell
migration directness reduced over time, with the nonmi-
gratory cells showing signiﬁcantly reduced cell directness
at 5 and 10 hours for both MSC types (unpaired Student’s
t-test, P < 0:05); however, after this, diﬀerences were not
seen, suggestive that with time both MSC types migrated in
a more random fashion.
Overall, these data provided new insights into BM and
periosteum MSC behaviour in culture. Smaller volumes of
BM MSCs could facilitate their faster migration capacities,
which in turn could in part explain their ability to form
larger colonies, compared to periosteal MSCs, in standard
CFU-F assays.
3.4. MSC Diﬀerentiation Capacity. Quantitative trilineage
diﬀerentiation assays were carried out on donor-matched
cultures in addition to qPCR for lineage-speciﬁc markers
comparing day 0 (before diﬀerentiation) and day 21
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Table 2: Summary of cell morphology of periosteum and bone
marrow cultures. Periosteum (P) vs. bone marrow (BM), unpaired
Student’s t-test, ∗∗∗∗P < 0:0001.
Cell
morphology
characteristic
Number of cells
measured
Average cell
thickness (μm)
Cell surface
area (μm2)
Dividing
P 51 6:1±2:5∗∗∗∗ 497 ± 172
BM 23 3:4 ± 0:6 493 ± 126
Spindle
P 2438 1:4±0:3∗∗∗∗ 827±414∗∗∗∗
BM 1061 1:3 ± 0:3 668 ± 297
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(following three weeks of diﬀerentiation induction). Osteo-
genic cultures were stained for ALP after two weeks and then
for calcium deposition after three weeks, where visually
similar staining could be seen for both culture types, with a
tendency for visually higher conﬂuency in the periosteum
cultures (Figure 5(b)). Calcium content was quantiﬁed
(n = 7) at three weeks and was found to be slightly higher
(but not signiﬁcant, Wilcoxon signed-rank test, P = 0:08) in
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Figure 4: Live cell tracking of migration patterns of periosteum and bone marrow cultures. (a) Cell migration map of individually tracked
cells with </>100μm mean cell migration, multiple cells represented. (b) Quantiﬁcation of cell migration, (c) cell motility, and (d) cell
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8 Stem Cells International
periosteum than BM cultures. Of note, there was high
donor variation that was not shown to correlate with
donor age (r2 value, 0.17 (BM), 0.22 (periosteum)). qPCR
showed reduction in the early osteogenic marker, RUNX2
expression, but increases in the late osteogenic marker
BGLAP expression at day 21 (n = 3) for both culture types,
as expected.
In chondrogenic conditions, after three weeks, pellets of
similar sizes were seen to form for periosteum and BM cul-
tures and staining for GAG (toluidine blue) was conﬁrmed
for both (Figure 5(b)). Following quantiﬁcation of GAG con-
tent, no signiﬁcant diﬀerences were seen between periosteum
and BM pellets (Wilcoxon signed-rank test, n = 5, P = 0:99)
(Figure 5(b)). As with osteogenesis, there was high donor
variability; however, donor age was seen to negatively aﬀect
GAG production for BM cultures (r2 = 0:77), but not perios-
teum cultures (r2 = 0:22). Chondrogenic diﬀerentiation
markers, COL2A1 and SOX9, were increased in both perios-
teum and BM pellets by day 21 (Figure 5(b)).
Noticeably, greater fat deposition was seen in BM cul-
tures compared to periosteum, following three weeks of adi-
pogenic induction and oil red staining (n = 6) (Figure 5(b)).
Quantiﬁcation of fat deposition (Nile red) and DNA (DAPI)
levels revealed that BM cultures had higher fat per cell
content (Wilcoxon signed-rank test, P < 0:05). FABP4 was
seen to increase in both culture types following adipogenic
induction (Figure 5(b)); however, PPAR-γ increased in BM
cultures but reduced in periosteum cultures.
4. Discussion
In this study, the potential for the utilisation of periosteum-
derived MSCs as a source of MSCs during bone defect surgi-
cal repair was investigated. Currently, there is a lack of direct
comparisons of MSCs derived from human periosteum and
BMA, especially when donor matched [24, 35]. Here, for
the ﬁrst time, donor-matched comparisons of “clinically
accessible” periosteum (from within the surgical opening of
a fracture site) were compared to iliac crest BMA, a supply
of MSCs currently used in surgery [36].
Both MSC sources were compared histologically to locate
CD271+ candidate MSCs within each tissue [21, 37–39]. The
cambium layer of periosteum has been historically described
as a rich source of osteoprogenitors, whereas the ﬁbrous layer
is thought to be less cellular [16, 17, 40, 41]. However, this
study has shown the presence of CD271+ cells in human
samples located throughout the outer ﬁbrous layer. These
cells were localised surrounding blood vessels throughout
the ﬁbrous layer; therefore, even though the cambium layer
was often not harvested, these data indicated that “clinically
accessible” human periosteum could still contain a supply
of MSCs.
CFU-F assays are the gold standard for MSC quantiﬁca-
tion in BM aspirates or solid connective tissues enzymatically
processed to release viable cells [42]. Despite this, very few
studies have so far quantiﬁed human periosteum MSC
frequency [20, 42] and none of them compared it to donor-
matched BMA. Our data on the 2500-fold higher frequency
of MSCs present within “clinically accessible” periosteum
samples, which most commonly do not include the cambium
layer, present periosteum as a viable alternative to BM aspi-
rates with high and consistent supply of MSCs. Of note, the
MSC counts within BM samples (0.0008%) in this study were
lower compared to the literature, which estimates 0.001-
0.01% MSC [43]. This could be due to the fact that most of
the BMA in our study were collected in large volumes
(>50mL) prior to concentration to generate BMAC, and
it is known to result in BM dilution with peripheral blood
[21, 32, 43]. Nevertheless, even at the highest MSC content
for BMA (0.0027%) within this study, the donor-matched
periosteum had >1500-fold more MSCs, thus conﬁrming
the superiority of periosteum samples with respect to their
MSC content.
Until recently, CFU-F colony size measurements have
not been routinely performed in MSC tissue comparison
studies; however, these data can provide valuable informa-
tion on MSC heterogeneity within the tissues under investi-
gation. When this was carried out on BM aspirates, MSC
subpopulations with diﬀerent sizes and densities have been
found indicating a high degree of MSC heterogeneity, which
in one study was linked to donor age [22] but could be also
related to diﬀerent MSC topographies [44, 45]. Here, perios-
teum colonies were signiﬁcantly smaller (half in size), and
more homogenous than donor-matched BM counterparts,
which aids in the predictability of periosteumMSC outcomes
over BM MSCs.
In order to underpin the diﬀerences seen in colony for-
mation between periosteum and BM MSC cultures, live cell
imaging of early in vitro (2 weeks in culture) MSCs was car-
ried out. Phase holographic imaging was utilised as a nonin-
vasive, unlabeled high throughput method for quantifying
cellular morphology and live cell tracking [46–48]. MSC
morphology in both MSC sources was variable over time,
changing hour by hour, with approximately 98% of the cells
measured retaining the classical “spindle” shape, and the
remaining 2% of the measured cells were retracted into
Table 3: Summary of conﬂuency, cell migration, and cell motility speed—split into nonmigratory and migratory cells, following cell tracking
of periosteum and bone marrow MSC cultures.
Passage 0 MSC culture
Conﬂuency (% cell
coverage)
Number of cells split by cell
migration (%)
Cell motility (μm/h)
0 hours 25 hours <100 μm >100 μm <100μm >100 μm
Periosteum 5:0 ± 1:2 9:9 ± 3:3 42.2 (n = 55) 57.8 (n = 26) 17.5 20.4
Bone marrow 0:9 ± 0:3 2:7 ± 0:6 62.8 (n = 59) 37.2 (n = 35) 22.3 32.0
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spheres, undergoing division. Similar proportions of dividing
cells seen in these experiments are consistent with our data
on similar growth rates between paired periosteum and BM
cultures prior to passage zero. Based on these and our
CFU-F data, we therefore hypothesised that smaller perios-
teum colony sizes could be due to their reduced cell area
and/or poorer ability for migration rather than their reduced
proliferation.
When individual cells were analysed over a 24-hour
period, it was observed that as MSCs proliferate and occupy
more surface, their migration plateaus and cell directness
becomes more random, for both cell types. Indeed, perios-
teumMSCs were less migratory and moving at slower speeds
than BM MSCs. This was also true when cells were divided
into two subpopulations, nonmigratory and migratory, based
on chosen arbitrary cut-oﬀ point of 100μm. The speed at
which MSCs migrate was also quantiﬁed; for the ﬁrst time,
periosteum MSCs were shown to migrate at 17.5μm/h
(nonmigratory) and 20.4μm/h (migratory), which was
slower than their BM MSC counterparts at 22.3μm/h
(nonmigratory) and 30.0μm/h (migratory). BM MSC
migration speed within a collagen type I gel has been quan-
tiﬁed previously in one study (15μm/h), which could reﬂect
that migration speed is inﬂuenced by the substrate on which
MSCs are in contact with [49]. This was also shown by
Salam et al. [50], whereby ﬁbrinogen matrix concentration
was shown to inversely aﬀect BM MSC migration, through
reduction in pore size and changes in substrate stiﬀness.
These characteristics may help to develop more rational
approaches for bone scaﬀold design for repopulation by
periosteal cells, for example, their optimal porosity. Related
to this, a recent study utilised holographic imaging to assess
growth and diﬀerentiation of BM MSCs onto a glass and a
titanium oxide (TiO2), showing favorable cell adhesion and
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Figure 5: Trilineage diﬀerentiation assays, comparing donor-matched periosteum and bone marrowMSCs. Each assay was assessed using (a)
histology staining, (b) quantitative assays, and (c) qPCR for speciﬁc markers of diﬀerentiation. Osteogenic assays stained for alkaline
phosphatase (fast blue) and calcium deposition (alizarin red), with quantiﬁed Ca2+ content and assessment of runt-related transcription
factor 2 (RUNX2) and bone gamma-carboxyglutamate (gla) protein (BGLAP) expression levels. Chondrogenic assay macro images (insert)
stained for glycosaminoglycans (GAG) (toluidine blue), quantiﬁed GAG content and collagen, type 2, alpha 1 (COL2A1), and SRY- (sex-
determining region Y-) box 9 (Sox9) expression levels. Adipogenic assays stained for fat deposition (oil red), quantiﬁed fat deposition
(Nile red) and nuclei content (DAPI), and fatty acid-binding protein 4 (FABP4) and peroxisome proliferator-activated receptor-gamma
(PPAR-γ) expression levels. Wilcoxon signed-rank test was carried out, ∗P < 0:05. Scale bars represent 500 μm (fast blue, alizarin red, and
oil red), 200μm (macro insert), and 200μm (toluidine blue). BM: bone marrow, P: periosteum, bd: below detection.
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spreading on the TiO2 coating [51], highlighting the poten-
tial of this technology in the tissue engineering ﬁeld. Future
work would aim at increasing donor numbers to assess
donor variability and impact of donor age, as well as a
more precise study of how cell conﬂuence aﬀects individual
cells’ behaviours.
With respect to cell size analysis, periosteum MSC cell
area was 20% larger compared to donor-matched BM cells.
This conﬁrmed that despite higher cumulative PDs
accrued by BMMSCs, they were not approaching senescence
(senescent cells are larger) [52], which is consistent with our
observations of similar proportions of dividing cells for both
MSC types. Although this investigation was limited to a sin-
gle pair of donor-matched cultures, the available evidence
points towards slower motility of early-culture periosteal
cells compared to BM cells in our experimental conditions,
rather than their lower proliferation or smaller cell area. A
larger cell surface area of periosteum MSCs could aﬀect the
traction forces required to overcome fractional and adhe-
sive resistances required to allow for cell movement [53].
Conﬂuence is another factor that can aﬀect cell velocity
or migration; however, this did not appear to inﬂuence
the seen diﬀerences in this study, thus other factors must
be at play.
We have shown that diﬀering tissue sources of MSCs,
from the same donor and grown in vitro for the same time
period, are potentially interacting with the same substrate
(in this case tissue culture plastic) in diﬀerent ways, thus
resulting in changes in cell surface area, migration distance,
and velocity. It is known that migration of spindle-shaped
cells, like MSCs, is dependent on the formation focal adhe-
sions with actin ﬁlaments that mechanically link the extracel-
lular matrix to the cytoskeleton and contractile stress ﬁbres
[53]. Levels of integrins and cytoskeleton within MSCs have
previously been linked to inﬂuencing MSC diﬀerentiation,
whereby increased focal adhesions and a stiﬀ spread cyto-
skeleton appear to inﬂuence osteogenesis [54]. Goessler
et al. [55] showed that adipose tissue MSCs and BM MSCs
grown in vitro express diﬀerent levels of various integrins,
which inﬂuence focal adhesion formation. However, little
is known about diﬀerences in integrin and focal adhesion
levels between periosteum and BM MSCs; future develop-
ments to this work would involve ascertaining whether
there are inherent diﬀerences in the cytoskeleton and focal
adhesion formation.
For periosteum to be utilised as a source of MSCs for
fracture healing, osteogenic and chondrogenic capacities are
of particular importance [56, 57]. While osteogenic and
chondrogenic diﬀerentiation capacities of periosteum MSC
cultures were shown to be similar to donor-matched BM
MSCs, adipogenic diﬀerentiation showed clear diﬀerences,
whereby periosteal adipogenic potential was signiﬁcantly
lower than donor-matched BM MSCs. Diﬀerences could be
partially explained through a reduction in PPAR-γ levels, a
molecule critical to initiating adipocyte diﬀerentiation [58],
in day 21 periosteum MSCs, whereas in BM MSCs, it was
upregulated, consistent with previous studies [24, 31].
Mastoid periosteum MSC clones showed variation in triline-
age diﬀerentiation capacity, whereby nearly all clones showed
osteochondral capacity, whereas only 53% were considered
to be adipogenic [59]. Based on this and our data, it could
be suggested that periosteum MSCs have a preferential
commitment to osteochondral diﬀerentiation, needed for
fracture repair.
As with harvesting of bone autograft for ﬁlling of critical
size bone defects, a key point to consider with advocating for
the use of periosteum is creating a minimal donor site mor-
bidity. Currently, free vascularised corticoperiosteal bone
grafts, where the periosteum and underlying cortical graft
bone can be 4 cm2, are harvested from the medial femoral
condyle, to wrap around a defect site [60–63]. The femoral
condyle is found to consolidate well following the harvesting
process [60, 61]. Additionally, proof-of-concept studies in
critical size bone defect sheep models have shown maximal
defect bridging, where autologous periosteal strips were used,
harvested with a periosteal elevator, thus removing the cam-
bium layer [64, 65]. Together, this suggests that harvesting
small graft(s) with a scalpel of the ﬁbrous layer of periosteum
as in this study, leaving the cambium mainly intact, would
not create a donor site morbidity. This would allow for peri-
osteum as a proliferative “MSC-rich” source to be trans-
planted into or around defect areas for the treatment of
complex fracture or critical size bone defects, as a conjunct
with other healing stimulating factors and cell sources that
are currently in use.
5. Conclusions
“Clinically accessible” samples of long bone periosteum, a
vital component of bone fracture repair has been shown to
be a rich source of highly proliferative MSCs, compared to
the current “gold-standard” BMA, with lower adipogenic
but similar osteochondral potential. A novel live cell tracking
technique permitted extensive quantiﬁcation of morpholog-
ical and migratory characteristics of periosteal MSCs that
can be used to inform the development of novel bone graft
substitutes to be repopulated by these cells. Further investi-
gation into “minimally manipulated” periosteum samples,
for example, periosteal micrografts, is needed for future
clinical translation of this tissue source for use during single
surgical procedure.
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